Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Arix Bioscience PLC (ARIX)
Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10-Aug-2022 / 18:05 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.